// App-Quantinova.ai

1862 : Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Researchers

Presenter

  • Peter Duggan

Principal Investigators

  • Kathy Gratton

  • Li Ren

  • Jordan Johnson

  • Jiri Slaby

  • Douglas A. Stewart

  • Jonathan J Keats

  • Nizar J. Bahlis

Medical Centers

  • University of Calgary, Southern Alberta Cancer Research Institute, Calgary, AB, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Multiple Myeloma

  • Thrombocytopenia

  • Peripheral neuropathy

  • Anemia

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Peripheral blood mononuclear cell

  • Creatinine

  • Human albumin

  • Syndecan-1

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Thalidomide

  • Bortezomib

  • Veliparib

  • ribose

Outcome

  • N/A

Study Design

  • pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved